LGVN vs. FGEN, STTK, NRXP, BRNS, JSPR, NBRV, ANVS, AADI, LTRN, and TPST
Should you be buying Longeveron stock or one of its competitors? The main competitors of Longeveron include FibroGen (FGEN), Shattuck Labs (STTK), NRx Pharmaceuticals (NRXP), Barinthus Biotherapeutics (BRNS), Jasper Therapeutics (JSPR), Nabriva Therapeutics (NBRV), Annovis Bio (ANVS), Aadi Bioscience (AADI), Lantern Pharma (LTRN), and Tempest Therapeutics (TPST). These companies are all part of the "pharmaceutical products" industry.
Longeveron vs. Its Competitors
FibroGen (NASDAQ:FGEN) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.
FibroGen has a net margin of -3.86% compared to Longeveron's net margin of -894.40%. FibroGen's return on equity of 0.00% beat Longeveron's return on equity.
72.7% of FibroGen shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 3.1% of FibroGen shares are held by insiders. Comparatively, 11.2% of Longeveron shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
FibroGen presently has a consensus price target of $43.00, suggesting a potential upside of 255.37%. Longeveron has a consensus price target of $7.67, suggesting a potential upside of 868.26%. Given Longeveron's stronger consensus rating and higher possible upside, analysts clearly believe Longeveron is more favorable than FibroGen.
In the previous week, Longeveron had 2 more articles in the media than FibroGen. MarketBeat recorded 3 mentions for Longeveron and 1 mentions for FibroGen. FibroGen's average media sentiment score of 0.00 beat Longeveron's score of -0.33 indicating that FibroGen is being referred to more favorably in the media.
Longeveron has lower revenue, but higher earnings than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.
FibroGen has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500.
Summary
FibroGen beats Longeveron on 9 of the 16 factors compared between the two stocks.
Get Longeveron News Delivered to You Automatically
Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LGVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Longeveron Competitors List
Related Companies and Tools
This page (NASDAQ:LGVN) was last updated on 9/6/2025 by MarketBeat.com Staff
Free LGVN Stock Alerts